In vitro assessment of inflammatory skin potential of poly(methyl methacrylate) at non‐cytotoxic concentrations
Source abstract
Abstract
Abstract Poly(methyl methacrylate) (PMMA) is considered an attractive substrate material for fabricating wearable skin sensors such as fitness bands and microfluidic devices. Despite its widespread use, inflammatory and allergic responses have been attributed to the use of this material. Therefore, the main objective of this study was to obtain a comprehensive understanding of potential biological effects triggered by PMMA at non‐cytotoxic concentrations using in vitro models of NIH3T3 fibroblasts and reconstructed human epidermis (RhE). It was hypothesized that concentrations that do not reduce cell viability are sufficient to activate pathways of inflammatory processes in the skin. The study included cytotoxicity, cell metabolism, cytokine quantification, histopathological, and gene expression analyses. The NIH3T3 cell line was used as a testbed for screening cell toxicity levels associated with the concentration of PMMA with different molecular weights (MWs) (i.e., MW ~5,000 and ~15,000 g/mol). The lower MW of PMMA had a half‐maximal inhibitory concentration (IC50) value of 5.7 mg/cm2, indicating greater detrimental effects than the higher MW (IC50 = 14.0 mg/cm2). Non‐cytotoxic concentrations of 3.0 mg/cm2 for MW ~15,000 g/mol and 0.9 mg/cm2 for MW ~5,000 g/mol) induced negative metabolic changes in NIH3T3 cells. Cell viability was severely reduced to 7% after the exposure to degradation by‐products generated after thermal and photodegradation degradation of PMMA. PMMA at non‐cytotoxic concentrations still induced overexpression of pro‐inflammatory cytokines, chemokines, and growth factors (IL1B, CXCL10, CCL5, IL1R1, IL7, IL17A, VEGFA, FGF2, IFNG, IL15) on the RhE model. The inflammatory response was also supported by histopathological and gene expression analyses of PMMA‐treated RhE, indicating tissue damage and gene overexpression. Results suggested that non‐cytotoxic concentrations of PMMA (3.0 to 5.6 mg/cm2 for MW ~15,000 g/mol and 0.9 to 2.1 mg/cm2 for MW ~5,000 g/mol) were sufficient to negatively alter NIH3T3 cells metabolism and activate inflammatory events in the RhE skin.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Advanced Sensor and Energy Harvesting Materials · Skin Protection and Aging · Contact Dermatitis and Allergies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Chemical Engineering University of Puerto Rico at Mayagüez Mayaguez Puerto Rico USA
Department of Chemistry University of Puerto Rico at Río Piedras San Juan Puerto Rico USA
Department of Industrial Engineering University of Puerto Rico at Mayagüez Mayaguez Puerto Rico USA
References (99)
Show source-provided references
1. 10.1002/adhm.20170002410.1002/adhm.201700024 ↗
2. 10.1038/s41746‐021‐00418‐310.1038/s41746‐021‐00418‐3 ↗
3. 10.1038/S41578‐022‐00460‐X10.1038/S41578‐022‐00460‐X ↗
4. 10.3390/nano906081310.3390/nano9060813 ↗
5. 10.1002/ADFM.20201038810.1002/ADFM.202010388 ↗
6. 10.1149/1945‐7111/AB697C10.1149/1945‐7111/AB697C ↗
7. 10.1016/J.BIOS.2016.09.03810.1016/J.BIOS.2016.09.038 ↗
8. 10.1098/RSIF.2019.021710.1098/RSIF.2019.0217 ↗
9. 10.3390/s1808241410.3390/s18082414 ↗
10. 10.1097/DER.000000000000057510.1097/DER.0000000000000575 ↗
11. 10.3390/MI803006910.3390/MI8030069 ↗
12. 10.3390/BIOS1208063010.3390/BIOS12080630 ↗
13. 10.1038/S41598‐018‐25202‐410.1038/S41598‐018‐25202‐4 ↗
14. 10.1021/ACSOMEGA.0C01770/SUPPL_FILE/AO0C01770_SI_001.PDF10.1021/ACSOMEGA.0C01770/SUPPL_FILE/AO0C01770_SI_001.PDF ↗
15. 10.1109/RBME.2021.312148010.1109/RBME.2021.3121480 ↗
16. 10.1007/S10404‐016‐1823‐1/TABLES/110.1007/S10404‐016‐1823‐1/TABLES/1 ↗
17. 10.1007/BF00263663/METRICS10.1007/BF00263663/METRICS ↗
18. 10.1021/JACS.8B12964/SUPPL_FILE/JA8B12964_SI_001.PDF10.1021/JACS.8B12964/SUPPL_FILE/JA8B12964_SI_001.PDF ↗
19. 10.1166/JNN.2016.1161010.1166/JNN.2016.11610 ↗
20. 10.1002/masy.20130019410.1002/masy.201300194 ↗
21. 10.1002/JBM.B.3450110.1002/JBM.B.34501 ↗
22. International Organization for Standardization.ISO 10993‐5: Biological Evaluation of Medical Devices‐Part 5: Tests for in Vitro Cytotoxicity.2009.
23. Emergency Care Research Institute (ECRI).Polymethyl Methacrylate Safety Profile Report for the U.S. FDA Center for Devices and Radiological Health.2021.
24. 10.1590/1807‐3107bor‐2018.vol32.003110.1590/1807‐3107bor‐2018.vol32.0031 ↗
25. 10.1007/S10143‐022‐01874‐5/FIGURES/310.1007/S10143‐022‐01874‐5/FIGURES/3 ↗
26. 10.1093/ASJ/SJV19510.1093/ASJ/SJV195 ↗
27. 10.1016/J.JACI.2019.12.52110.1016/J.JACI.2019.12.521 ↗
28. 10.1016/J.ENVRES.2003.11.00410.1016/J.ENVRES.2003.11.004 ↗
29. 10.1016/J.ETAP.2016.06.03010.1016/J.ETAP.2016.06.030 ↗
30. 10.1515/MGMC‐2017‐0023/MACHINEREADABLECITATION/RIS10.1515/MGMC‐2017‐0023/MACHINEREADABLECITATION/RIS ↗
31. 10.1016/J.MSEC.2015.10.04310.1016/J.MSEC.2015.10.043 ↗
32. 10.1109/COMST.2017.273197910.1109/COMST.2017.2731979 ↗
33. 10.1109/EMBC.2015.731878510.1109/EMBC.2015.7318785 ↗
34. Li D · 2020
35. 10.1038/424870A10.1038/424870A ↗
36. 10.1016/B978‐0‐12‐824315‐2.00673‐410.1016/B978‐0‐12‐824315‐2.00673‐4 ↗
37. 10.3389/FMOLB.2020.0003310.3389/FMOLB.2020.00033 ↗
38. 10.5114/AOMS.2016.6374310.5114/AOMS.2016.63743 ↗
39. 10.1787/9789264203884‐en10.1787/9789264203884‐en ↗
40. International Organization for Standardization.ISO 10993‐23: Tests for Irritation; Switzerland.2021.
41. 10.1016/J.JPUBECO.2021.10448210.1016/J.JPUBECO.2021.104482 ↗
42. ArezskiN CobbA WilliamsA BrownB.Dermal Compositions Containing Unatural Hygroscopic Amino Acids. WO 2014/072747 A1 2014.
43. 10.1016/J.TIV.2018.01.00810.1016/J.TIV.2018.01.008 ↗
44. 10.2147/IJN.S26258210.2147/IJN.S262582 ↗
45. 10.1093/MUTAGE/17.3.26110.1093/MUTAGE/17.3.261 ↗
46. 10.1016/J.IJPHARM.2017.02.04810.1016/J.IJPHARM.2017.02.048 ↗
47. 10.1002/bit.25664/abstract10.1002/bit.25664/abstract ↗
48. 10.1002/3527600418.MB8062E002610.1002/3527600418.MB8062E0026 ↗
49. 10.1002/jbm.82028060310.1002/jbm.820280603 ↗
50. 10.1007/978‐1‐4939‐6960‐9_710.1007/978‐1‐4939‐6960‐9_7 ↗
51. TechnologiesA.Agilent Technologies Agilent Seahorse XF Cell Mito Stress Test Kit User Guide; Wilmington.2019.
52. 10.1016/J.XPRO.2020.10024510.1016/J.XPRO.2020.100245 ↗
53. 10.3389/FENDO.2021.629239/BIBTEX10.3389/FENDO.2021.629239/BIBTEX ↗
54. 10.1096/FJ.202000767R10.1096/FJ.202000767R ↗
55. 10.1210/ENDREV/BNAA00510.1210/ENDREV/BNAA005 ↗
56. 10.1038/S41580‐019‐0123‐510.1038/S41580‐019‐0123‐5 ↗
57. 10.1016/J.CELL.2012.02.03210.1016/J.CELL.2012.02.032 ↗
58. 10.1158/1535‐7163.MCT‐18‐076610.1158/1535‐7163.MCT‐18‐0766 ↗
59. 10.1002/MNFR.20200099410.1002/MNFR.202000994 ↗
60. 10.1042/CS2014010110.1042/CS20140101 ↗
61. 10.1111/BPH.1351810.1111/BPH.13518 ↗
62. 10.1038/s41598‐020‐80708‐010.1038/s41598‐020‐80708‐0 ↗
63. 10.1093/HMG/DDR49410.1093/HMG/DDR494 ↗
64. 10.1016/J.CLINDERMATOL.2011.08.00710.1016/J.CLINDERMATOL.2011.08.007 ↗
65. 10.18632/ONCOTARGET.2320810.18632/ONCOTARGET.23208 ↗
66. 10.1186/S40824‐021‐00228‐4/FIGURES/710.1186/S40824‐021‐00228‐4/FIGURES/7 ↗
67. 10.1016/J.BBI.2021.04.01610.1016/J.BBI.2021.04.016 ↗
68. 10.1016/J.BBI.2019.04.01910.1016/J.BBI.2019.04.019 ↗
69. 10.1111/1523‐1747.EP1287605310.1111/1523‐1747.EP12876053 ↗
70. 10.1159/00028206210.1159/000282062 ↗
71. 10.1517/14728222.2013.83788610.1517/14728222.2013.837886 ↗
72. 10.1172/JCI3613010.1172/JCI36130 ↗
73. 10.3390/IJMS2023600810.3390/IJMS20236008 ↗
74. 10.1002/jor.110012011110.1002/jor.1100120111 ↗
75. 10.1016/0142‐9612(92)90173‐l10.1016/0142‐9612(92)90173‐l ↗
76. 10.1186/S12989‐019‐0291‐7/FIGURES/610.1186/S12989‐019‐0291‐7/FIGURES/6 ↗
77. 10.1155/2021/666502810.1155/2021/6665028 ↗
78. 10.1002/CAM4.325110.1002/CAM4.3251 ↗
79. 10.3390/DIAGNOSTICS12030676/S110.3390/DIAGNOSTICS12030676/S1 ↗
80. 10.1002/JCP.2975310.1002/JCP.29753 ↗
81. 10.3389/fonc.2021.63809910.3389/fonc.2021.638099 ↗
82. 10.1186/S12935‐020‐01599‐910.1186/S12935‐020‐01599‐9 ↗
83. 10.1038/S41598‐021‐81495‐Y10.1038/S41598‐021‐81495‐Y ↗
84. 10.3892/IJMM.2015.2079/HTML10.3892/IJMM.2015.2079/HTML ↗
85. 10.1016/J.REDOX.2017.02.01210.1016/J.REDOX.2017.02.012 ↗
86. 10.1016/J.MRGENTOX.2021.50340510.1016/J.MRGENTOX.2021.503405 ↗
87. RayPD HuangB‐W TsujiY.Reactive Oxygen Species (ROS) Homeostasis and Redox Regulation in Cellular Signaling.2012. doi:10.1016/j.cellsig.2012.01.00810.1016/j.cellsig.2012.01.008 ↗
88. Food and Drug Administration.Conveying Materials Information about Medical Devices to Patients and Healthcare Providers: Considerations for a Framework.2021.
89. 10.1016/J.POLYMDEGRADSTAB.2007.11.01910.1016/J.POLYMDEGRADSTAB.2007.11.019 ↗
90. AbouelezzM WatersPF.Studies on the Photodegradation of Poly(Methyl Methacrylate); Washington DC.1978. doi:10.6028/NBS.IR.78‐146310.21236/ADA304535 ↗
91. 10.1063/1.172754310.1063/1.1727543 ↗
92. 10.1016/b978‐0‐12‐809923‐0.00014‐x10.1016/b978‐0‐12‐809923‐0.00014‐x ↗
93. 10.1016/J.POLYMDEGRADSTAB.2004.11.02410.1016/J.POLYMDEGRADSTAB.2004.11.024 ↗
94. 10.1016/0022‐3913(80)90038‐410.1016/0022‐3913(80)90038‐4 ↗
95. 10.1002/JBM.A.3465210.1002/JBM.A.34652 ↗
96. 10.1021/acsbiomaterials.5b0042910.1021/acsbiomaterials.5b00429 ↗
97. 10.7717/PEERJ.86810.7717/PEERJ.868 ↗
98. International Organization for Standardization.ISO 10993‐12: Biological Evaluation of Medical Devices‐Part 12: Sample Preparation and Reference Materials; Switzerland.2012.
99. 10.3390/IJMS2111401610.3390/IJMS21114016 ↗